<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1337">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01713400</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16743</org_study_id>
    <nct_id>NCT01713400</nct_id>
  </id_info>
  <brief_title>Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease</brief_title>
  <acronym>Ustekinumab</acronym>
  <official_title>Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gateway for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether treatment with ustekinumab will alter the ratio of Treg/total CD4+
      cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a comparative study to assess the biologic and clinical activity of the agent
      ustekinumab when given in concert with our established regimen of SIR/TAC. Patients will be
      randomly assigned between the standard regimen of tacrolimus/sirolimus (TAC/SIR + placebo)
      vs. the investigational regimen of tacrolimus/sirolimus/ustekinumab (TAC/SIR/U) in a 1:1
      scheme.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treg/total CD4+ ratio</measure>
    <time_frame>30 days post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treg/total CD4+ ratio at day 30 following HCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Graft vs. Host Disease</measure>
    <time_frame>100 days post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of acute graft vs. host disease will be characterized weekly from day of transplant to day 100 using the 1995 updated grading scheme for GVHD developed by Glucksberg, et al.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Graft vs. Host Disease</condition>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ustekinumab, Tacrolimus and Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tacrolimus, and Sirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>One subcutaneous injection will be administered on day -1 and repeated on day +20 after transplant</description>
    <arm_group_label>Ustekinumab</arm_group_label>
    <other_name>STELARA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) will be administered via the identical route and schedule as ustekinumab.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologic disorder requiring allogeneic hematopoietic cell transplantation

          -  Adequate vital organ function:

          -  Left ventricular ejection fraction (LVEF) &gt;/= 45% by MUGA scan

          -  FEV1, FVC, and diffusing lung capacity oxygenation (DLCO) &gt;/= 50% of predicted values
             on pulmonary function tests

          -  Transaminases (AST, ALT) &lt; 3 times upper limit of normal values

          -  Creatinine clearance &gt;/= 50 cc/min.

          -  Performance status:  Karnofsky Performance Status Score &gt;/= 60%.

        Exclusion Criteria:

          -  Active infection not controlled with appropriate antimicrobial therapy

          -  HIV, hepatitis B, or hepatitis C infection

          -  Sorror's co-morbidity factors with total score &gt; 3

          -  Important modification to co-morbidity index calculation: DLCO will not be included
             in assessment of pulmonary risk, excepting those with DLCO &lt; 50%, who will merit a
             score of 3 and thereby be excluded from the trial.

          -  Anti-thymocyte globulin (ATG) as part of the conditioning regimen

          -  Cyclophosphamide as part of the conditioning regimens
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Pidala, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Graft vs. Host Disease (aGVHD)</keyword>
  <keyword>Graft vs. Host Disease (GVHD)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
